SBFM Q4 2024 Earnings — Sunshine Biopharma, Inc. Revenue & Financial Results | Market Cap Arena

SBFMSunshine Biopharma, Inc.

$6M

Q4 2024 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$10M+24.9% YoY

Gross Profit

$3M32.2% margin

Operating Income

-$2M-21.2% margin

Net Income

-$2M-22.5% margin

EPS (Diluted)

$-0.84

QoQ Revenue Growth

+13.8%

Cash Flow

Operating Cash Flow

-$3M

Free Cash Flow

-$4M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$31M

Total Liabilities

$7M

Stockholders' Equity

$24M

Cash & Equivalents

$10M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$10M	$8M	+24.9%
Gross Profit	$3M	$3M	+20.4%
Operating Income	-$2M	-$1M	-71.7%
Net Income	-$2M	-$1M	-72.6%